BloodFlow, a healthtech startup focused on turning routine blood test results into immediate, actionable insights for clinicians, has raised €1.2 million in seed funding.
The investment in the Lisbon-based company comes from 3xP Global’s Health Innovation Fund, a private equity firm headquartered in the Portuguese capital, known for its strong focus on ESG – environmental, social, and governance – principles and its hands-on approach in the Iberian market.
BloodFlow’s technology integrates smoothly into hospital systems via a plug-and-play API, delivering rapid, medically accurate, and explainable interpretations of blood diagnostics.
Unlike broader AI tools, BloodFlow focuses exclusively on blood test analysis, providing insights tailored for clinical use. This allows physicians to save time, increase diagnostic precision, and ultimately improve patient care.
According to BloodFlow, its platform has automatically analyzed over 50,000 patient reports, helped reduce clinician review and transcription time by an average of 95%, and achieved a 98.3% interpretation accuracy – validated by leading institutions. The company also estimates that automating blood test review can lead to annual savings of up to €320,000 in clinical settings.
The funding will accelerate BloodFlow’s growth, supporting expansion of the team, entry into new markets, and a retrospective clinical study to obtain medical device certification.
Additionally, the company plans to broaden its commercial and regulatory efforts, including new applications such as assisting pharmaceutical companies with blood test analysis during clinical trials.
“We are thrilled to have 3xP Global as a strategic investor in BloodFlow’s journey. Their investment brings invaluable expertise and support as we scale our solution to transform clinical workflows and improve patient outcomes across Europe,” Tiago Cunha Costa, founder and CEO of BloodFlow, said.
Raúl Saraiva, chief scientific officer and venture partner at 3xP Global, noted that the firm was drawn to BloodFlow’s focused, infrastructure-level approach and its potential to make better use of clinical data to drive personalization and accelerate the shift from curative to preventative medicine.
“We’re excited to back a team turning everyday diagnostics into high-impact, real-time decisions that truly move the needle on healthspan,” he added.
Featured image: From left to right: Raúl Saraiva, chief scientific officer and venture partner at 3xP Global; Tiago Cunha Costa, founder and CEO of BloodFlow; and Duarte Costa, founder and managing partner at 3xP Global (Photo courtesy of 3xP Global)
Portugal Startup News 